Home/Stacks/Wolverine Recovery Stack
RECOVERY STACK

Wolverine Recovery Stack

The most-researched soft-tissue repair combination — BPC-157 anchored with TB-500 for systemic cellular migration.

Educational overview only — not medical advice. No compound in this stack is presented as a treatment for any condition. Any protocol decision is a conversation with your licensed healthcare provider.

About This Stack

The Wolverine Stack is the best-known peptide combination in injury-recovery research. It pairs two compounds with complementary mechanisms: BPC-157 drives local angiogenesis and tissue repair at the injury site, while TB-500 drives systemic actin remodeling and cell migration that brings repair signaling to the whole body.

Users typically research this combination for tendon, ligament, and muscle injuries where standard physical therapy has plateaued. The two compounds have non-overlapping mechanisms — BPC-157's short half-life makes it a daily local-action compound, while TB-500's ~2-day half-life makes it a weekly systemic signal. This is why the pairing is so commonly discussed: they are not redundant.

No compound here is presented as a treatment. This is an educational overview of a combination users commonly research and discuss with their licensed healthcare provider.

Why These Compounds Are Researched Together

BPC-157 and TB-500 are pharmacologically complementary, not overlapping. BPC-157 acts locally — nitric oxide regulation, VEGF-driven angiogenesis, direct gut-mucosa and connective-tissue effects. TB-500 (synthetic thymosin beta-4 fragment) regulates actin polymerization, which matters for cell migration during repair. Local repair (BPC-157) plus the systemic migration signal (TB-500) is why this stack outperforms either compound alone in community reports.

Compounds in the Wolverine Recovery Stack

BPC-157ANCHOR
Body Protection Compound-157
Local tissue-repair signal with multi-pathway activity (NO, VEGF, dopamine). Applied near the injury site or systemically.
TB-500SYNERGIST
Thymosin Beta-4 (TB-500)
Systemic cell-migration and actin-remodeling signal. Weekly dosing complements BPC-157's daily cadence.

Biomarkers Users Commonly Track

When running a stack like this, these biomarkers let users see how the compounds perform in context. Trended across draws, they reveal whether the stack is actually moving the markers it should — or producing unintended shifts that warrant a provider conversation.

INFLAMMATION
hs-CRP
Tracks systemic inflammation — useful baseline and post-cycle delta during soft-tissue recovery.
NUTRIENT
Ferritin
Elevated ferritin can indicate ongoing inflammation; trending with recovery signals.
GROWTH
IGF-1
Optional — useful when recovery stack overlaps with any GH-axis protocol.

Typical Cycle

Community reports describe 4–8 week cycles for acute injuries, longer for chronic tendinopathy. Any cycling decision is a conversation with a licensed clinician.

What to Discuss With Your Provider

Both compounds are research-only (not FDA-approved for human use). A licensed provider can help evaluate the quality of underlying evidence, source of material, and whether the stack is appropriate for your specific injury pattern and medical history.

Related Stacks

RECOVERY
Injury Rehabilitation Stack
BPC-157 + TB-500 + Thymosin Beta-4 — the expanded tissue-repair combination for post-surgical and chronic-injury research.
AESTHETIC
Glow Stack
GHK-Cu + Epithalon + BPC-157 — the skin, collagen, and cellular-aging combination users research for aesthetic outcomes.
Track the Wolverine Recovery Stack against your labs.

Log every compound in the stack, upload your lab PDFs, and chart the biomarkers on this page across every draw. StackAI reads the panel in context of what you’re running.

Start tracking free →
Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to compounds describe what users research and typically discuss with their clinician — not endorsements, prescriptions, or treatment recommendations. Research-stage compounds discussed are not FDA-approved unless specifically noted. Any protocol decision requires a licensed healthcare provider.